AstraZeneca Lifted By Tagrisso Combo Lung Cancer Data
Shows Improvement Over Monotherapy
Data from the FLAURA2 trial suggest AstraZeneca could soon be able to expand use of Tagrisso in the first-line setting, widening the gap over Johnson & Johnson’s Rybrevant.
